Ecstasy (3,4-methylenedioxymethamphetamine): History, neurochemistry, and toxicology

Journal of the American Board of Family Practice

Volumn 12, Issue 2, 1999, Pages 137-142

  Rochester, Capt James A ^a  

^a Department of Family and Community Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANOREXIGENIC AGENT; DANTROLENE; DESIGNER DRUG;

ADULT; ARTICLE; CASE REPORT; COLLAPSE; DIAPHORESIS; DRUG CLASSIFICATION; DRUG INTOXICATION; DRUG OVERDOSE; EUPHORIA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTHERMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROCHEMISTRY; NEUROTOXICOLOGY; ORAL DRUG ADMINISTRATION; RECREATION; SELF CONCEPT; SUBSTANCE ABUSE;

EID: 0032921968     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: 10.3122/jabfm.12.2.137     Document Type: Article

References (14)

1. Shulgin AT. The background and chemistry of MDMA. J Psychoactive Drugs 1986;18:291-304.
2. Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18;319-27.
3. Lister MB, Grob CS, Bravo GL, Walsh RN. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 1992;180: 345-52.
4. Cregg MT, Tracey JA. Ecstasy abuse in Ireland. Ir Med J 1993;86:118-20.
5. Cuomo MJ, Dyment PG, Gammino VM. Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus. J Am Coll Health 1994: 42:271-4.
6. Wright JD, Pearl L. Knowledge and experience of young people regarding drug misuse, 1969-94. BMJ 1995;310:20-4.
7. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhr HJ, DeSouza EB. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H] paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987;242:911-6.
8. Brodkin J, Malyala A, Nash JF. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 1993;45:647-53.
9. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987;241:338-45.
10. McKenna DJ, Peroutka SJ. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").J Neurochem 1990;54:14-22.
11. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 1990;600:649-64.
12. O'Hearn E, Battaglia G, DeSouza EB, Kuhr MJ, Molliver ME. Methylenedioxyamphetamin (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988;8:2788-803.
13. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 1992;648:371-82.
14. Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (+ -)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations.; Pharmacol Exp Ther 1992;261:616-22.